



## Research of Bacteriophages Antimicrobial Activity

Guest Editor:

**Dr. Barbara Dolegowska**

Department of Microbiology,  
Immunology and Laboratory  
Medicine, Pomeranian Medical  
University in Szczecin, Szczecin,  
Poland

Deadline for manuscript  
submissions:

**closed (30 June 2021)**

### Message from the Guest Editor

Dear Colleagues,

The bacteriophages are our allies in the fight against drug-resistant bacteria that deserve our undivided attention. In particular, the ability of phages to infect and destroy bacterial cells poses a possibility to replace traditional antimicrobial therapies or to use them together within phage antibiotic combined therapy. A great deal of phage research also reveals the unique evolutionary trajectories and their important role in shaping the environmental microbiome. This Special Issue seeks manuscript submissions that further our understanding of the antimicrobial activity of the bacteriophages. Submissions on the bacteriophage biology, role of phages in shaping the human/animal microbiome, phage genetic engineering, bacterial host resistance, the influence of external factor on phage activity, and phage-antibiotic synergy are especially encouraged.

**Keywords:** bacteriophages; phage therapy; phage ecology, phage biocontrol; phage antibiotic synergy; antimicrobial resistance; phages protein; endolysins





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)